MAP2K5 and lung adenocarcinoma: Based on the precedent that transgenic mice expressing a constitutively active MEK5 form developed lung adenocarcinomas, we decided to explore the potential relationship between expression of the pathway components MEK5 and ERK5 and patient outcome.